BEN-28010
/ BenevolentAI
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 27, 2025
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of Glioblastoma.
(PubMed, J Med Chem)
- "In vivo pharmacological studies demonstrated efficacy of orally administered 38 in several GBM CDX and PDX models as a monotherapy and in combination with ionizing radiation, including improved overall survival in an intracranially implanted GBM PDX mouse model. Additionally, 38 utilizes an underrepresented aminoimidazole kinase hinge-binding motif that may have broader utility within kinase inhibitor drug discovery."
Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CHEK1
March 14, 2024
BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023
(Businesswire)
- "Successfully progressed glioblastoma multiforme (GBM) asset to IND-ready status. BEN-28010 is an oral brain-penetrant CHK1 inhibitor for the treatment of GBM and metastatic brain tumours which completed regulatory IND-enabling studies during the year to plan."
Clinical • Glioblastoma
September 21, 2023
BenevolentAI: Interim Results for the Six Months Ended 30 June 2023
(Businesswire)
- "BEN-28010, a CHK1 inhibitor for Glioblastoma Multiforme (GBM) and metastatic brain tumours, remains on track and is expected to be IND-ready by Q4 2023."
IND • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
March 16, 2023
BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022
(Businesswire)
- "BEN-2293...A topical potentially best-in-class PanTrk inhibitor in development to relieve inflammation and rapidly resolve the itch in patients with atopic dermatitis (AD). Completed a Phase IIa study and expect top-line data by the end of March 2023. BEN-8744...An oral peripherally-restricted small molecule PDE10 inhibitor under development as a first-in-class treatment for ulcerative colitis (UC) and with potential for other indications within inflammatory bowel diseases....expect to initiate a Phase I clinical trial in H1 2023. BEN-28010...An orally administered asset under development as a best-in-class treatment for glioblastoma multiforme (GBM). Declared as a clinical candidate in July 2022, with preparation for IND-enabling studies ongoing. The asset could be ready for Phase I studies in 2024."
New P1 trial • P2a data • Atopic Dermatitis • Glioblastoma • Glioma • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Solid Tumor • Ulcerative Colitis
September 27, 2022
BenevolentAI Interim Results for the Six Months Ended 30 June 2022
(Businesswire)
- "BEN-28010 is an orally administered asset we are developing as a best-in-class treatment for glioblastoma multiforme...Preparation for IND-enabling studies ongoing. Subject to positive data the asset will then be ready for Phase I studies in 2024."
New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology
1 to 5
Of
5
Go to page
1